J&J to Sell Remaining Stake in Kenvue Spinoff
By Dean Seal
Johnson & Johnson plans to unload its remaining 9.5% stake in Kenvue in a public offering set about a year after it started splitting off the Tylenol and Benadryl maker.
Kenvue said Monday that it will launch a secondary underwritten offering for 182.3 million shares that Johnson & Johnson is providing in a debt-for-equity exchange with Goldman Sachs and JP Morgan.
If sold at Friday's closing price of $20.54, the offering would fetch around $3.75 billion.
Kenvue said that Johnson & Johnson will no longer own any of its stock once the offering is completed.
Johnson & Johnson held an initial public offering for Kenvue a year ago and then sold most of its shares in the company in August.
The healthcare giant previously said it wanted to untangle the consumer-health unit's finances and operations from its prescription-drugs and medical device businesses. The effort followed similar moves by Pfizer and Merck, which sold their consumer-health businesses.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 13, 2024 10:06 ET (14:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now